Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Meta Expands AI Training With Employee Activity Tracking Tools 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
BURLINGAME, Calif., March 13, 2017 -- Corvus Pharmaceuticals Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, announced that the company will postpone its R&D Day scheduled for March 14, 2017 due to an anticipated severe winter snowstorm forecasted to hit the New York tri-state area and its impact on the travel schedule and participation of its principal presenters.
The company plans to reschedule the event within the first half of 2017 and will provide details of the rescheduled event as soon as that date is determined.
The company anticipates providing additional updates on its lead CPI-444 program as planned at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2017, which is taking place April 1-5 in Washington, D.C.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
Tecentriq® is a registered trademark of Genentech.
Corvus Contact: Jason Coloma SVP, Chief Business Officer Corvus Pharmaceuticals, Inc. +1-650-900-4511 [email protected] Media Contact Julie Normart Pure Communications +1-415-946-1087 [email protected]
